Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2
作者:Pengxuan Ren、Changyue Yu、Ruxue Zhang、Tianqing Nie、Qiaoyu Hu、Hui Li、Xianglei Zhang、Xueyuan Zhang、Shiwei Li、Lu Liu、Wenhao Dai、Jian Li、Yechun Xu、Haixia Su、Leike Zhang、Hong Liu、Fang Bai
DOI:10.1016/j.ejmech.2023.115129
日期:2023.3
treatment of corona virus disease 2019 (COVID-19). In this study, a series of 2,3,5-substituted [1,2,4]-thiadiazole analogs were discovered to be able to inhibit 3CLpro as non-peptidomimetic covalent binders at submicromolar levels, with IC50 values ranging from 0.118 to 0.582 μM. Interestingly, these compounds were also shown to inhibit PLpro with the same level of IC50 values, but had negligible effect
3C 样蛋白酶 (3CL pro ) 对于严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的复制和转录至关重要,使其成为治疗 2019 年冠状病毒病 (COVID-19) 的有希望的靶点。在这项研究中,发现一系列 2,3,5-取代的 [1,2,4]-噻二唑类似物能够抑制 3CL pro作为亚微摩尔水平的非拟肽共价结合剂,IC 50值范围为 0.118至 0.582 μM。有趣的是,这些化合物还显示出以相同水平的IC 50抑制 PL pro值,但对胰凝乳蛋白酶、组织蛋白酶 B 和组织蛋白酶 L 等蛋白酶的影响可忽略不计。随后,在基于细胞的测定中评估了这些化合物的抗病毒能力,化合物 6g 显示出有效的抗病毒活性,EC 50值为7.249 μM . 有人提出,这些化合物通过开环复分解反应机制与催化性半胱氨酸 145 共价结合。为了理解这种共价结合反应,我们选择了化合物6a,作为已确